MOTIVATION LETTER The Conjunctive Consolidation Threshold model proposes a testable mechanism for preventing reward-memory encoding in addiction. Three sole-authored preprints on OSF and Zenodo, a provisional patent filed Q3 2026, and endorsements from Kent Berridge, Samuel Gershman, Nathaniel Daw, and Marcelo Mattar demonstrate that this work has already achieved a level of scientific maturity and peer recognition typically associated with a completed PhD. The Wellcome Early-Career Award is the appropriate vehicle to transition this independent research programme into a formal, funded trajectory that includes a PhD at the Medical University of Graz while continuing the CCT's development toward clinical translation. Nigeria carries a disproportionate burden of substance use disorders with minimal pharmacological innovation tailored to its population. The CCT model, validated through ODE/RK45 simulations and Bayesian MCMC showing an 85.8 percent reduction in encoding probability and a 12.8 percentage point super-additivity effect, offers a framework deployable in low-resource settings where existing treatments are either unavailable or ineffective. My platforms IMPRINT, TOPOLOGIX, and GATE represent a parallel commitment to building open-source computational tools that address addiction liability screening, drug-protein interaction analysis, and neural-stimulation safety evaluation directly relevant to the Nigerian context. The award would support a structured PhD at MUG/Graz under supervision aligned with computational neuroscience, while funding continued independent development of the CCT's clinical trial architecture already specified in the Zenodo preprint. Wellcome's mission to improve human health through transformative research aligns with the CCT's potential to shift addiction treatment from symptom management to mechanism-based prevention. My track record of producing a coherent body of work, securing a provisional patent, and collaborating with leading researchers without formal doctoral training demonstrates the independence and initiative this programme seeks to support. RESEARCH STATEMENT The CCT model addresses a fundamental gap in addiction neuroscience: no existing pharmacological intervention directly prevents the encoding of reward-memory associations that drive compulsive drug-seeking. Current treatments target either acute intoxication, withdrawal symptoms, or relapse prevention through receptor antagonism or substitution therapy. None interrupt the conjunctive consolidation process by which dopamine and glutamate signals jointly stabilise drug-context memories during the post-reward window. The model specifies three simultaneous pharmacological interventions: a dopamine D1 receptor partial agonist to normalise phasic dopamine signalling, an NMDA receptor antagonist to reduce glutamatergic plasticity, and a beta-adrenergic receptor blocker to attenuate noradrenergic memory consolidation. Computational validation using coupled ODE systems solved via RK45 and Bayesian population dynamics with MCMC sampling confirmed all five pre-registered hypotheses H1 through H5. Encoding probability dropped from 0.855 to 0.122, representing an 85.8 percent reduction. The combination showed super-additivity of 12.8 percentage points beyond the sum of individual effects, supporting the conjunctive mechanism. The proposed work during the award period has three aims. First, refine the mathematical specification of the CCT to incorporate individual variability in dopamine transporter density, NMDA receptor subunit composition, and beta-adrenergic receptor polymorphisms using hierarchical Bayesian models. Second, validate the model against existing rodent and human datasets through secondary analysis of published microdialysis, fMRI, and behavioural data, with specific attention to temporal windows of consolidation. Third, design a Phase I clinical trial protocol for a fixed-dose combination of low-dose haloperidol, memantine, and propranolol, building on the trial architecture already specified in the Zenodo preprint. This protocol will be submitted for ethical review in Nigeria, use the LMIC perspective that Wellcome values. The provisional patent on the CCT core architecture protects the combinatorial formulation and its dosing schedule. The review article under consideration at Neuroscience and Biobehavioral Reviews will establish the theoretical foundation in the peer-reviewed literature. The award would fund the computational infrastructure, data access, and supervisory support needed to complete these aims and submit the clinical trial protocol within three years. CAREER DEVELOPMENT PLAN The Wellcome Early-Career Award will support a structured PhD at the Medical University of Graz starting October 2026, while maintaining my independent research identity and the CCT programme. The PhD will provide formal training in computational neuroscience methods, specifically in advanced Bayesian statistics, neural network modelling of reinforcement learning, and clinical trial design, areas where my current self-taught expertise requires formal accreditation for future independent funding applications. Year one focuses on completing the mathematical refinement of the CCT model and submitting the clinical trial protocol for ethical review. Year two involves validation against existing datasets and preparation of two manuscripts for high-impact journals. Year three consolidates the PhD dissertation and submits a follow-up Wellcome Career Development Award application to support the Phase I trial in Nigeria. Supervision at MUG/Graz will be complemented by continued collaboration with Berridge, Gershman, Daw, and Mattar, who have endorsed the CCT work and agreed to serve as external advisors. The award will also fund attendance at two international conferences per year, including the Society for Neuroscience and the Computational and Systems Neuroscience meeting, to present findings and build the network necessary for post-PhD independence. My long-term goal is to establish a computational neuroscience and pharmacology research group based in Lagos, focused on developing and testing mechanism-based interventions for substance use disorders prevalent in West Africa. The Wellcome Early-Career Award is the critical first step in this trajectory, providing the funding, training, and institutional backing to transform an independent research programme into a sustainable academic career. INSTITUTIONAL SUPPORT LETTER REQUEST I request a letter of support from the Medical University of Graz confirming my acceptance into their PhD programme in Computational Neuroscience for the October 2026 intake, detailing the supervisory arrangement, access to HPC facilities, and commitment to providing office and laboratory space. The letter should specify that the Wellcome Early-Career Award funds will be administered through the university's grants office, with appropriate overhead arrangements. Contact: Professor [name], Department of [department], Medical University of Graz, Auenbruggerplatz 2, 8036 Graz, Austria. CHECKLIST - [ ] Completed Wellcome Early-Career Award application form - [ ] Motivation letter (this document) - [ ] Research statement (this document) - [ ] Career development plan (this document) - [ ] CV with ORCID, GitHub, and publication list - [ ] Three preprints on OSF and Zenodo with DOIs - [ ] Provisional patent filing documentation - [ ] Endorsement letters from Kent Berridge, Samuel Gershman, Nathaniel Daw, and Marcelo Mattar - [ ] Institutional support letter from Medical University of Graz - [ ] Two academic reference letters (one from a previous supervisor, one from a collaborator) - [ ] Proof of PCN pharmacist license - [ ] B.Pharm degree certificate and transcript - [ ] Nigerian passport copy for LMIC verification EDITOR NOTES - Eligibility risk: Wellcome Early-Career Awards typically require a PhD or equivalent research experience. Eniola must explicitly argue equivalence through preprints, patent, and endorsements. The programme may require a formal host institution; MUG/Graz acceptance letter is critical. - The institutional support letter from MUG/Graz is not yet secured. The applicant must initiate contact with the potential PhD supervisor and confirm willingness to host the award before submission. - The provisional patent filing date is listed as Q3 2026. If the application is submitted before Q3 2026, the patent may be listed as pending. Verify the exact filing status and include the application number if available.